1.Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.
Jaemin JO ; Se Hyun KIM ; Yu Jung KIM ; Juhyun LEE ; Miso KIM ; Bhumsuk KEAM ; Tae Min KIM ; Dong Wan KIM ; Dae Seog HEO ; Jin Haeng CHUNG ; Yoon Kyung JEON ; Jong Seok LEE
Yonsei Medical Journal 2018;59(2):202-210
PURPOSE: Previous retrospective studies suggest that anaplastic lymphoma kinase (ALK) mutation-positive (ALK+) non-small cell lung cancer (NSCLC) patients are sensitive to pemetrexed. To determine its efficacy, we retrospectively evaluated clinical outcomes of pemetrexed-based chemotherapy in patients with ALK+ NSCLC. MATERIALS AND METHODS: We identified 126 patients with advanced, ALK+ NSCLC who received first-line cytotoxic chemotherapy. We compared response, progression-free survival (PFS), and overall survival (OS) rates according to chemotherapy regimens. Furthermore, we evaluated intracranial time to tumor progression (TTP) and proportion of ALK+ cells as prognostic factors. RESULTS: Forty-eight patients received pemetrexed-based chemotherapy, while 78 received other regimens as first-line treatment. The pemetrexed-based chemotherapy group showed superior overall response (44.7% vs. 14.3%, p < 0.001) and disease control (85.1% vs. 62.3%, p=0.008) rates. The pemetrexed-based chemotherapy group also exhibited longer PFS (6.6 months vs. 3.8 months, p < 0.001); OS rates were not significantly different. The lack of exposure to second-generation ALK inhibitors and intracranial metastasis on initial diagnosis were independent negative prognostic factors of OS. Intracranial TTP was similar between the treatment groups (32.7 months vs. 35.7 months, p=0.733). Patients who harbored a greater number of ALK+ tumor cells (≥70%) showed prolonged OS on univariate analysis (not reached vs. 44.8 months, p=0.041), but not on multivariate analysis (hazard ratio: 0.19, 95% confidence interval: 0.03–1.42; p=0.106). CONCLUSION: Pemetrexed-based regimens may prolong PFS in patients with ALK+ NSCLC as a first-line treatment, but are not associated with prolonged OS. Exposure to second-generation ALK inhibitors may improve OS rates in patients with ALK+ NSCLC.
Adult
;
Aged
;
Antineoplastic Agents/*therapeutic use
;
Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/mortality
;
Disease-Free Survival
;
Female
;
Humans
;
Lung Neoplasms/*drug therapy/enzymology/mortality
;
Male
;
Middle Aged
;
Mutation
;
Pemetrexed/*therapeutic use
;
Receptor Protein-Tyrosine Kinases/genetics
;
Retrospective Studies
;
Survival Rate
;
Treatment Outcome
2.Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy in Advanced NSCLC Patients with EGFR Mutations.
Minjiang CHEN ; Yan XU ; Jing ZHAO ; Wei ZHONG ; Mengzhao WANG
Chinese Journal of Lung Cancer 2019;22(2):99-104
BACKGROUND:
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated some dramatic efficacy in advanced non-small-cell lung cancer (NSCLC) patients with activating EGFR mutation. However, progression-free survivals (PFS) among those patients who were treated with first line EGFR TKIs were inconsistent. The aim of this study is to explore the association of clinical prognostic factors with EGFR-TKI efficacy in advanced NSCLC patients.
METHODS:
The demographic and clinical characteristics of 203 patients with activating EGFR mutation treated with first generation TKI as a first-line therapy were retrospectively reviewed.
RESULTS:
Of the 203 patients enrolled in this study, 139 patients had progression of disease and 63 patients died. The subjects had a median follow up duration of 21.1months and a median PFS of 14.3 months. Partial response (PR) was achieved in 127 (66.1%) patients and stable disease (SD) rate was achieved in 55 (28.6%) patients. In univariate analysis, patients with 2 or higher ECOG score (5.1 vs 16 months, P=0.033), SD as best overall response (9.5 vs 17.9 months, P=0.030), extrathoracic metastasis (11.7 vs 27.5 months, P=0.004), liver metastasis (4.1 vs 16.0 months, P=0.000), bone metastasis (13.3 vs 21.5months, P=0.027) and pulmonary embolism (5.5 vs 16.6 months, P=0.005) had shorter PFS than those without the listed factors. Multivariable Cox regression analysis showed best overall response (HR=1.825, 95%CI: 1.107-3.008, P=0.018) and liver metastasis (HR=1.694, 95%CI: 1.146-5.756, P=0.022) were independent predictive factors of shorter PFS.
CONCLUSIONS
Despite the high efficacy of EGFR-TKI, SD as best overall response and liver metastasis predicts poorer PFS in advanced NSCLC patients with EGFR gene mutations receiving first-line therapy treatment.
Adult
;
Aged
;
Antineoplastic Agents
;
administration & dosage
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
enzymology
;
genetics
;
mortality
;
ErbB Receptors
;
genetics
;
metabolism
;
Female
;
Humans
;
Lung Neoplasms
;
drug therapy
;
enzymology
;
genetics
;
Middle Aged
;
Mutation
;
Protein Kinase Inhibitors
;
administration & dosage
;
Retrospective Studies
;
Treatment Outcome
;
Young Adult
3.Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma.
Jeong Won JANG ; Seong Tae PARK ; Jung Hyun KWON ; Chan Ran YOU ; Jong Young CHOI ; Chan Kwon JUNG ; Si Hyun BAE ; Seung Kew YOON
Experimental & Molecular Medicine 2011;43(5):305-312
Although continuous low-dose (metronomic [MET]) therapy exerts anti-cancer efficacy in various cancer models, the effect of long-term MET therapy for hepatocellular carcinoma (HCC) remains unknown. This study assessed the long-term efficacy of MET on suppression of tumor growth and spontaneous metastasis in a rat model of HCC induced by administration of diethylnitrosamine for 16 wk. The rats were divided into 3 groups: MTD group received intraperitoneal (i.p.) injections of 40 mg/kg cyclophosphamide on days 1, 3, and 5 of a 21-day cycle; Control and MET groups received i.p. injections of saline and 20 mg/kg cyclophosphamide twice a week, respectively. Anti-tumor and anti-angiogenic effects and anti-metastatic mechanisms including matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) were evaluated. Twelve wk of MET therapy resulted in a significant reduction in intrahepatic tumors than control or MTD therapy. The MET group had fewer proliferating cell nuclear antigen-positive cells and decreased hypoxia-inducible factor-1alpha levels and microvessel density. Lung metastases were detected in 100%, 80%, and 42.9% in the control, MTD, and MET groups, respectively. MET therapy significantly decreased expression of TIMP-1, MMP-2 and -9. For mediators of pro-MMP-2 activation, MET therapy induced significant suppression in the TIMP-2 and MMP-14 level. The survival in the MET group was significantly prolonged compared to the control and MTD groups. Long-term MET scheduling suppresses tumor growth and metastasis via its potent anti-angiogenic properties and a decrease in MMPs and TIMPs activities. These results provide a rationale for long-term MET dosing in future clinical trials of HCC treatment.
Animals
;
Antineoplastic Agents/*administration & dosage/*pharmacology
;
Carcinoma, Hepatocellular/chemically induced/*drug therapy/mortality/pathology
;
Cell Proliferation/drug effects
;
Cyclophosphamide/*administration & dosage/*pharmacology
;
Diethylnitrosamine
;
Disease Models, Animal
;
Gene Expression Regulation, Neoplastic/*drug effects
;
Liver Cirrhosis/chemically induced
;
Liver Neoplasms/chemically induced/*drug therapy/mortality/pathology
;
Lung Neoplasms/drug therapy/pathology/secondary
;
Male
;
Matrix Metalloproteinases/metabolism
;
Neovascularization, Pathologic/enzymology/physiopathology
;
Rats
;
Rats, Sprague-Dawley
;
Survival Analysis
;
Tissue Inhibitor of Metalloproteinases/metabolism
;
Tumor Burden/drug effects